Abstract
The recent identification of c-kit-positive cardiac stem cells revealed the great growth reserve of the heart, in which connection among cells might be essential in regulating their fate. Especially, the mircrine mechanism, translocation of microRNAs (miRs) from a cell to another via gap junctions, appeared to be important in controlling the differentiation of cardiac stem cells. The modification on miR expression and/or translocation may be able to enhance further the clinical efficacy of cellular therapy.
INTRODUCTION
The heart had been considered post-mitotic and terminally differentiated. However, the identification of resident c-kit-positive cardiac stem cells in the adult mammalian heart, especially in humans (), has challenged this long-lasting dogma; the myocardium turned out to be continuously and dynamically renewed by the activation, migration, and differentiation of the stem cell compartment (). In general, tissue stem cells are stored in a specialized structure called “niche” and protected from external unfavorable stimuli (). In the human heart, cardiac stem cells exist in the interstitial spaces among matured cardiomyocytes, namely “cardiac niches” (Figure 1A), where the primitive cells form gap and adherens junctions with surrounding myocytes and fibroblasts (Figures 1B,C) that function as supporting cells in the structure ().
FIGURE 1
MYOCARDIAL REGENERATION BY CARDIAC STEM CELLS
When c-kit-positive human cardiac stem cells are injected to the area close to the infarcted myocardium of immunosuppressed rats, muscles and vessels are regenerated improving significantly the ventricular function (
Although the number of the regenerated cardiomyocytes may exceed that of the lost muscle cells of the host (
RNA INTERFERENCE BY microRNAs
MicroRNAs (miRs) are a class of small non-coding RNAs that are evolutionally well-conserved and negatively regulate gene expression by repressing protein translation and/or by promoting mRNA degradation. These short RNAs are not uniformly distributed in the organism but show a preferential localization that is organ and cell specific. One miR is considered to target hundreds of mRNA, whereas one mRNA is interfered by multiple miRs; this complex network is regulating numerous biological processes including development, propagation, specification, and senescence. In the cardiovascular system, the roles of many miRs have been disclosed (
As for the targets of miR-499, genes involved in differentiation, SOX6 and PTBP3 hold in their 3′-untranslated regions (3′-UTRs) well-conserved miR-499 binding sequences. In fact, whereas the transcripts of these genes are abundant in cardiac stem cells and cardiomyocytes, the corresponding protein expressions are minimal only in the myocyte compartment (
THE MIRCRINE PHENOMENON
When rat neonatal myocytes, serving as the “donor” cells, and enhanced green fluorescent protein (EGFP)-labeled human cardiac stem cells, representing the “recipient” cells, were co-cultured for 36 h, in situ hybridization revealed miR-499 appearing in 35% of the recipient cells; in the presence of the gap junction inhibitor, however, the percentage decreased to less than half (
In order to visualize the translocation of miRs, fluorochrome Cy3-labeled miR-499 was synthesized and microinjected to human cardiac stem cells in culture. Under the microscopic observation, the fluorescent dye was transferred from the injected cell to the neighboring cells (
FIGURE 2

(A) The repressive activity of translocated miR-499 (miR) on the 3′-untranslated region of SOX6 gene is abolished by the gap junction inhibitor (+α-GA). Blank indicates donor cells transfected with empty plasmid. *P < 0.05 vs. blank; **P < 0.05 vs. miR. (B) Schematic representation of the “mircrine” mechanism: the translocation of miRs from a donor cell to a recipient cell via gap junctions.
miR-499 AND THE CARDIAC STEM CELL FATE
By overexpressing miR-499 in cardiac stem cells, the amount of SOX6 and PTBP3 proteins decreases. This modification is accompanied by augmented differentiation of the cells into myocyte lineage as documented by the expression of myocyte-specific antigens NKX2-5 and GATA4. Additionally, the introduction of siRNA against SOX6 and PTBP3 genes, respectively, enhances similarly the myocytic commitment, which indicates the function of miR-499 through SOX6 and PTBP3 inhibitions (
CLOSING REMARKS
Recently, c-kit-positive cardiac stem cells were used clinically. In this SCIPIO trial, autologous stem cells were infused into the coronary artery bypass graft (CABG) vessels of the severe heart failure patients 4 months after the operation. Compared with the control group treated with bypass surgery only, the cellular therapy resulted in the remarkable augmentation of cardiac performance accompanied by the improved symptom (
Statements
Acknowledgments
Toru Hosoda was supported by the Grant-in-Aid for Scientific Research (C) 25461118 (Japan Society for the Promotion of Science: JSPS).
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
REFERENCES
1
BearziC.RotaM.HosodaT.TillmannsJ.NascimbeneA.De AngelisA.et al (2007). Human cardiac stem cells.Proc. Natl. Acad. Sci. U.S.A.10414068–14073. 10.1073/pnas.0706760104
2
BolliR.ChughA. R.D’AmarioD.LoughranJ. H.StoddardM. F.IkramS.et al (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.Lancet3781847–1857. 10.1016/S0140-6736(11)61590-0
3
ChughA. R.BeacheG. M.LoughranJ. H.MewtonN.ElmoreJ. B.KajsturaJ.et al (2012). Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance.Circulation126S54–S64. 10.1161/CIRCULATIONAHA.112.092627
4
D’AmarioD.Cabral-Da-SilvaM. C.ZhengH.FioriniC.GoichbergP.SteadmanE.et al (2011). Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration.Circ. Res.1081467–1481. 10.1161/CIRCRESAHA.111.240648
5
DawnB.SteinA. B.UrbanekK.RotaM.WhangB.RastaldoR.et al (2005). Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function.Proc. Natl. Acad. Sci. U.S.A.1023766–3771. 10.1073/pnas.0405957102
6
FuchsE.TumbarT.GuaschG. (2004). Socializing with the neighbors: stem cells and their niche.Cell116769–778. 10.1016/S0092-8674(04)00255-7
7
GoichbergP.BaiY.D’AmarioD.Ferreira-MartinsJ.FioriniC.ZhengH.et al (2011). The ephrin A1-EphA2 system promotes cardiac stem cell migration after infarction.Circ. Res.1081071–1083. 10.1161/CIRCRESAHA.110.239459
8
HosodaT.ZhengH.Cabral-da-SilvaM.SanadaF.Ide-IwataN.OgórekB.et al (2011). Human cardiac stem cell differentiation is regulated by a mircrine mechanism.Circulation1231287–1296. 10.1161/CIRCULATIONAHA.110.982918
9
KajsturaJ.KajsturaJ.GurusamyN.OgórekB.GoichbergP.Clavo-RondonC.et al (2010). Myocyte turnover in the aging human heart.Circ. Res.1071374–1386. 10.1161/CIRCRESAHA.110.231498
10
SmallE. M.FrostR. J.OlsonE. N. (2010). MicroRNAs add a new dimension to cardiovascular disease.Circulation1211022–1032. 10.1161/CIRCULATIONAHA.109.889048
Summary
Keywords
mircrine, microRNA, c-kit, cardiac stem cells, gap junctions
Citation
Hosoda T (2013) The mircrine mechanism controlling cardiac stem cell fate. Front. Genet. 4:204. doi: 10.3389/fgene.2013.00204
Received
31 August 2013
Accepted
24 September 2013
Published
10 October 2013
Volume
4 - 2013
Edited by
Halyna R. Shcherbata, Max Planck Society, Germany
Reviewed by
Ian C. G. Weaver, Dalhousie University, Canada; Fabiola Olivieri, Università Politecnica delle Marche, Italy
Copyright
© Hosoda.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Toru Hosoda, Institute of Innovative Science and Technology, Tokai University, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan e-mail: hosoda@tokai-u.jp
This articlewas submitted to Epigenomics and Epigenetics, a section of the journal Frontiers in Genetics.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.